Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trialResearch in context
Summary: Background: SOBERANA-02 is a COVID-19 conjugate vaccine (recombinant RBD conjugated to tetanus toxoid). Phases 1/2 clinical trials demonstrated high immunogenicity, promoting neutralising IgG and specific T-cell response. A third heterologous dose of SOBERANA-Plus (RBD-dimer) further increa...
Saved in:
Similar Items
-
Real-world effectiveness of the heterologous SOBERANA-02 and SOBERANA-Plus vaccine scheme in 2-11 years-old children during the SARS-CoV-2 Omicron wave in Cuba: a longitudinal case-population studyResearch in context
by: María Eugenia Toledo-Romaní, et al.
Published: (2024) -
La colonia soberana deportes olímpicos, Identidad nacional y política internacional en Puerto Rico
by: Sotomayor, Antonio
Published: (2020) -
Role of the ACTH test and estimation of a safe dose for high potency steroids in vitiligo: A prospective randomized study
by: Alberto de la Fuente-García, et al.
Published: (2014) -
Vaccine coverage and compliance in Mexico with the two-dose and three-dose rotavirus vaccines
by: Gerardo Luna-Casas, et al.
Published: (2019) -
WaveOne Gold, un nuevo instrumento reciprocante para la conformación de los conductos radiculares WaveOne Gold, a new reciprocating instrument for root canals shaping
by: Denise Alfie, et al.
Published: (2017)